How doctors treat multiple myeloma that stops responding to drugs

This is a real-world study following people with relapsed or refractory multiple myeloma (a blood cancer that has come back or stopped responding to previous treatments) over 24 months. Researchers will observe and collect information about how patients are treated with talquetamab and other standard medications used in routine cancer care. The study aims to understand how well these treatments work and how they affect patients' quality of life.

Multiple myeloma can become resistant to initial treatments, leaving patients and doctors with difficult choices about what to try next. This study helps researchers understand which treatments work best in real-world settings and how to support patients better when their cancer stops responding to earlier therapies.